Dose ranges reflect commonly studied amounts in published research models. This is not medical advice. For research use only. Not for human consumption.
Protocol Comparison
Skin & Hair
Research dose range
Standard research range
250 - 500 mcg
Common loading-phase convention — interpolated between the low-start dose and the trial-anchored dose below, not independently sourced at this exact range.
Research focus
Melanogenesis / Dual Pigmentation
Observed window
Visible darkening 3-7 days; peak color 2-4 weeks
Administration
Daily(loading)/Weekle
Primary pathway
MC1R / MC3R / MC4R
Dose data anchored to the 1996 Dorr et al. Phase 1 trial (0.025mg/kg SC, weight-based) and community low-dose tolerance protocols. Total published human trial population is approximately 33 people. For research use only.
PROTOCOL BENEFITS
◆
Activates MC1R on melanocytes to trigger genuine melanogenesis — the same biological process UV exposure uses, without requiring the UV.
◆
Also engages MC4R in the hypothalamus, which is why this specific compound class carries a documented secondary effect on sexual arousal.
◆
Backed by real human dose-response data from 1990s Arizona research — genuine clinical grounding, though the program was small and never advanced past early trials.
SCIENCE
MT-2 is a synthetic analog of alpha-MSH, engineered to be more potent and longer-lasting than the natural hormone. What sets it apart from more targeted melanocortin compounds is its lack of selectivity — it activates MC1R, MC3R, and MC4R all at once, which is exactly why one compound produces tanning, appetite suppression, and arousal effects together.
MT-2's tanning mechanism is genuine melanogenesis, not surface coloring — the same pathway UV exposure uses. That's also the source of its most serious open question: multiple melanoma case reports exist in MT-2 users, and the biological plausibility of a link is real, since the compound works by driving melanocyte activity. The published trial population — around 33 people total — is too small to establish actual cancer risk, but it's also too small to rule it out.
WHAT TO EXPECT
Visible darkening typically begins within 3-7 days, building toward peak color over 2-4 weeks of continued dosing.
PROTOCOL NOTE
Available in 10mg. For research use only. Full documentation included with every order.
FAQ
MT-2 doesn't selectively target one receptor — it activates MC1R for pigmentation and MC4R for central arousal pathways simultaneously, which is why both effects appear from a single compound.
Nausea, particularly with the first few doses — documented at meaningful rates in published trials, though it tends to diminish with continued use.
